CV Sciences (CVSI) Cash from Financing Activities (2011 - 2026)
CV Sciences (CVSI) reported Cash from Financing Activities of -$68000.0 for Q1 2026, down 114.17% on a YoY basis from $480000.0 in Q1 2025, and down 126.36% sequentially from $258000.0 in Q4 2025.
CV Sciences (CVSI) Cash from Financing Activities (2011 - 2026) Analysis & Trends
CV Sciences (CVSI) has 16 years of Cash from Financing Activities data on file, last reported at -$68000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities fell 114.17% year-over-year to -$68000.0; the trailing twelve-month figure through Mar 2026 stood at -$211000.0 (down 132.56% YoY), and the FY2025 full-year result was $337000.0, up 953.12% from the prior year.
- Cash from Financing Activities retreated to -$68000.0 in Q1 2026, from $258000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $1.4 million in Q1 2022 to a low of -$872000.0 in Q1 2023.
- A 5-year average of $1823.5 and a median of -$87000.0 in 2024 frame the typical range for Cash from Financing Activities.
- Peak annual rise in Cash from Financing Activities reached 2207.14% in 2024, while the deepest fall reached 498.21% in 2024.
- Tracing CVSI's Cash from Financing Activities over 5 years: stood at -$738000.0 in 2022, then surged by 92.41% to -$56000.0 in 2023, then tumbled by 498.21% to -$335000.0 in 2024, then soared by 177.01% to $258000.0 in 2025, then plunged by 126.36% to -$68000.0 in 2026.
- Business Quant data shows CVSI's Cash from Financing Activities at -$68000.0 in Q1 2026, $258000.0 in Q4 2025, and -$234000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | CV Sciences | 3.74 Mn | 3.43 Mn | 1.56 Mn | -68,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -68,000.00 |
| Mar 31, 2026 | -68,000.00 |
| Dec 31, 2025 | 258,000.00 |
| Dec 31, 2025 | 258,000.00 |
| Sep 30, 2025 | -234,000.00 |
| Sep 30, 2025 | -234,000.00 |
| Jun 30, 2025 | -167,000.00 |
| Jun 30, 2025 | -167,000.00 |
| Mar 31, 2025 | 480,000.00 |
| Mar 31, 2025 | 480,000.00 |
| Dec 31, 2024 | -335,000.00 |
| Dec 31, 2024 | -335,000.00 |
| Sep 30, 2024 | 590,000.00 |
| Sep 30, 2024 | 590,000.00 |
| Jun 30, 2024 | -87,000.00 |
| Jun 30, 2024 | -87,000.00 |
| Mar 31, 2024 | -136,000.00 |
| Mar 31, 2024 | -136,000.00 |
| Dec 31, 2023 | -56,000.00 |
| Dec 31, 2023 | -56,000.00 |